Align Technology (ALGN)
(Delayed Data from NSDQ)
$212.15 USD
+1.37 (0.65%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $211.69 -0.46 (-0.22%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$212.15 USD
+1.37 (0.65%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $211.69 -0.46 (-0.22%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth C Momentum C VGM
Zacks News
Zacks.com featured highlights PRA Health Sciences, Align Technology, Adobe Systems and Par Pacific Holdings
by Zacks Equity Research
Zacks.com featured highlights PRA Health Sciences, Align Technology, Adobe Systems and Par Pacific Holdings
Deep Learning Goes to Wall Street
by Kevin Cook
Fintech innovations are changing investing tools and behavior in powerful ways that you must begin to explore.
Buy These 4 Top-Ranked Profitable Stocks in November
by Zacks Equity Research
A profitable company is able to meet all its operating costs and offer stupendous returns to its investors.
Align Technology (ALGN) Q3 Earnings Top on Invisalign Sales
by Zacks Equity Research
An extremely strong summer teen season drives Align Technology's (ALGN) Invisalign growth within the global teen market in the third quarter.
Will S.E.T. Arm Drive Zimmer Biomet's (ZBH) Q3 Earnings?
by Zacks Equity Research
Zimmer Biomet (ZBH) poised to gain on strength in S.E.T as well as Spine & CMF segments in Q3.
Henry Schein (HSIC) Q3 Earnings to Show Growth in All Lines
by Zacks Equity Research
Henry Schein (HSIC) likely to gain on strength across all business segments in Q3.
What's in Store for Penumbra (PEN) Stock in Q3 Earnings?
by Zacks Equity Research
Penumbra (PEN) is expected to gain from strong performance by its neuro and peripheral vascular arms in Q3.
Can Companion Animal Group Drive IDEXX's (IDXX) Q3 Earnings?
by Zacks Equity Research
IDEXX Laboratories (IDXX) is poised to gain from strength in its Companion Animal Group business in Q3.
Will Invisalign Drive Align Technology's (ALGN) Q3 Earnings?
by Zacks Equity Research
Align Technology (ALGN) is poised to gain from strength in the Invisalign space in Q3.
Varian Medical (VAR) Q4 Earnings: Is a Surprise in Store?
by Zacks Equity Research
We are upbeat about Varian Medical's oncology business that accounted for around 95% of the company's total revenue in fourth-quarter 2017.
Baxter International (BAX) Q3 Earnings: What's in Store?
by Zacks Equity Research
Baxter International Inc's (BAX) third quarter estimate revision trend is encouraging due to acquisitions and strategic collaborations to enhance its product portfolio.
Walgreens Boots (WBA) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Walgreens Boots (WBA) may witness another quarter of prescription growth and strength in Retail Pharmacy USA division in Q4 earnings.
Can Illumina (ILMN) Maintain Balanced Growth in Q3 Earnings?
by Zacks Equity Research
Illumina (ILMN) might gain from continued growth in Product as well as Service and other segments in the third quarter.
Will Edwards Lifesciences (EW) Gain on THVT in Q3 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) will likely ride high in Q3 earnings banking on continued growth in its highly advanced Transcatheter Heart Valve Therapy space.
Will Recall Issue Hurt Boston Scientific (BSX) Q3 Earnings?
by Zacks Equity Research
Although Boston Scientific's (BSX) recent $435-million acquisition of Symetis SA might drive its IC business, the company's full recovery post a primary product recall may however, take time.
Can Nutrisystem (NTRI) Surprise Investors in Q3 Earnings?
by Zacks Equity Research
Nutrisystem's (NTRI) innovative products are expected to expand customer base that will eventually drive reactivation revenues in Q3.
What to Expect From Thermo Fisher (TMO) in Q3 Earnings
by Zacks Equity Research
Thermo Fisher (TMO) gears up for another quarter of strong analytical instruments segmental growth. Improvement is likely to be seen in applied markets too.
Will Intuitive Surgical (ISRG) Disappoint in Q3 Earnings?
by Zacks Equity Research
We believe that the growing adoption of Intuitive Surgical's (ISRG) da Vinci system among physicians for general surgery, oncology, urology and gynecology procedures is a catalyst for the quarter.
Can CR Bard (BCR) Spring a Surprise This Earnings Season?
by Zacks Equity Research
We believe that the growing adoption of the company's flagship Lutonix drug coated-balloon will result in improved performance for CR Bard (BCR) in Q3.
Can ResMed (RMD) Maintain Balanced Growth in Q1 Earnings?
by Zacks Equity Research
ResMed (RMD) may ride high in Q1 on continued growth in its domestic as well as overseas business.
$200 Club Bullish Stampede
by Kevin Cook
These 5 growth stocks are leading the charge and keeping their promise to hit $200 sooner than even I imagined.
Gaming the Stock Market with Poker Smarts
by Kevin Cook
Technical analysis and probability skills are essential, but behavioral analysis will take you to the pro's table.
Align Technology (ALGN) Prospects Bright, Competition Rife
by Zacks Equity Research
Align Technology (ALGN) continues to gain from strong InvisAlign sales amid macroeconomic headwinds.
The Zacks Analyst Blog Highlights: iShares Core S&P 500 ETF, Vertex Pharmaceuticals, Align Technology, NRG Energy and Activision Blizzard
by Zacks Equity Research
The Zacks Analyst Blog Highlights: iShares Core S&P 500 ETF, Vertex Pharmaceuticals, Align Technology, NRG Energy and Activision Blizzard
Align Technology at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Align Technology's (ALGN) efforts to expand worldwide instil confidence in investors. The market is upbeat about the non-exclusive distribution agreement with Patterson Dental.